For a peptide whose reputation rests almost entirely on tendon, muscle and ligament repair, the most consequential human data on thymosin beta-4 has just landed somewhere else entirely: a coronary care unit. A randomised, double-blind, placebo-controlled trial of recombinant human thymosin β4 in 96 people having a heart attack was published in Cardiovascular Research — and its headline result was a miss. If you've been searching "what is TB-500", "TB-500 research" or "is TB-500 legal in Australia", this trial is worth understanding, because it's the closest thing the molecule has to a real efficacy test in humans, and it didn't clear the bar.

What the heart attack trial actually tested

The study paired mouse work with a human trial. In C57BL/6J mice subjected to ischaemia/reperfusion injury, seven days of recombinant human thymosin β4 (rhTβ4) prevented cardiac dysfunction and fibrosis at 28 days and lowered plasma NT-proBNP. RNA sequencing pointed to the ErbB signalling pathway, and in cell models the peptide activated ErbB2/Raf1 signalling and reduced cardiomyocyte apoptosis. Blocking ErbB2 abolished the benefit — a clean mechanistic story, in animals.

The human arm was the interesting part. Ninety-six patients with ST-elevation myocardial infarction (STEMI) were randomised after percutaneous coronary intervention to rhTβ4 or placebo, with infarct area measured at 90 days.

The overall between-group difference in infarct area was not statistically significant.

A reduction was reported in the group whose first dose went in within eight hours of PCI (n = 43). That's a timing-based subgroup, and the published abstract doesn't make clear whether that split was locked in before the data were unblinded. Either way, a subgroup finding in a trial that missed overall is hypothesis-generating, not proof. It tells you where to point the next trial; it doesn't tell you the drug works.

Why "it missed" is still useful information

This matters because the cardiac hypothesis is the oldest and best-funded idea in the thymosin β4 literature — the cardioprotection work in animals goes back to the mid-2000s. Two decades of promising rodent data have now produced one modest, equivocal human signal. That's a realistic benchmark for anyone weighing the far thinner evidence behind the injury-recovery claims made for TB-500 online.

It's also a reminder of how these trials are actually run: intravenous dosing, in hospital, minutes-to-hours after a defined injury event, with MRI-measured endpoints. Nothing about that design transfers to a person self-administering a peptide at home for a sore Achilles.

TB-500 and thymosin β4 are not the same input

Worth restating plainly, because it's where most online summaries go wrong. The trial used recombinant human thymosin β4 — the full 43-amino-acid protein the body makes. What's sold as "TB-500" is generally a short synthetic fragment built around the LKKTETQ actin-binding region, often N-acetylated. It's a related molecule, not the same one, with different size, different pharmacokinetics and no published human efficacy trials of its own.

So a cardiac result in full-length rhTβ4 is not a result for TB-500, and a positive finding in one wouldn't automatically validate the other. That distinction is also why anti-doping laboratories had to build separate assays: detecting synthetic N-acetylated LKKTETQ against a background of naturally occurring thymosin β4 is a genuinely hard analytical problem, first tackled in equine doping control in the early 2010s.

Is TB-500 legal in Australia? The regulatory position

Australia's position is among the strictest in the world, and it hasn't loosened.

  • Following a scheduling review of performance and image enhancing drugs, thymosin beta-4 and TB-500 were added to Schedule 4 and to Appendix D, Item 5 of the Poisons Standard, with the Appendix D possession controls in force since June 2016.
  • Schedule 4 means prescription-only. Appendix D Item 5 goes further: possession without authority — that is, other than under a lawful prescription — is an offence. That is a meaningfully higher bar than most Schedule 4 medicines.
  • There is no TGA-registered thymosin β4 product for injury recovery, or for anything else. No thymosin β4 drug has been approved by any major regulator to date.
  • It is prohibited at all times under the WADA Code as a growth factor, and banned in racing jurisdictions. In January 2016, the Court of Arbitration for Sport upheld anti-doping violations against 34 Essendon players in a case centred on thymosin beta-4 — still the defining Australian episode for this compound.

The practical upshot for Australian readers: this is not a grey-area supplement here. It's a scheduled substance with possession controls, sitting on an evidence base that has not yet produced a single positive human trial for the use it's best known for. We don't cover sourcing — you can read our broader peptide profiles for how other compounds compare on evidence and regulatory status.

What would change the picture

Three things, in order of weight:

  1. A larger, pre-specified STEMI trial testing the sub-8-hour dosing window. That's the obvious next step, and the Cardiovascular Research result is exactly the kind of finding that justifies one. An earlier Phase II programme in acute myocardial infarction was registered on ClinicalTrials.gov under Chinese sponsor Beijing Northland Biotech; whether a confirmatory Phase III follows is the thing to watch.
  2. Any controlled human trial in musculoskeletal injury. There still isn't one. Every tendon, muscle and ligament claim you'll read traces to animal models or cell culture.
  3. Published head-to-head data on the fragment versus the full protein. Until that exists, extrapolating from rhTβ4 trials to TB-500 is an assumption, not a finding.

Want these trials tracked as they read out, without the marketing gloss? Join the free updates list.

FAQ

Is TB-500 legal in Australia?

TB-500 and thymosin beta-4 are Schedule 4 (prescription-only) and listed in Appendix D, Item 5 of the Poisons Standard, meaning possession without a lawful prescription is an offence. No product is TGA-registered for injury recovery.

Did the thymosin beta-4 heart attack trial work?

No — the 96-patient randomised trial published in Cardiovascular Research found no statistically significant overall difference in infarct area at 90 days. A reduction was reported only in the subgroup dosed within eight hours of PCI, which is hypothesis-generating rather than conclusive.

Does TB-500 heal injuries?

There are no published human trials showing TB-500 speeds recovery from tendon, muscle or ligament injury. The injury-repair rationale rests on animal and cell-culture research, which frequently fails to replicate in people.

Is TB-500 banned in sport?

Yes. Thymosin beta-4 and TB-500 are prohibited at all times under the WADA Code as growth factors, and are banned in horse racing. The Court of Arbitration for Sport upheld violations against 34 Essendon players in January 2016 in a case centred on thymosin beta-4.

Sources

Not medical advice. Thymosin beta-4 / TB-500 is investigational and not approved by the TGA or any major regulator for any indication; in Australia it is Schedule 4 with Appendix D possession controls. retatrutide.net.au is independent and not affiliated with any manufacturer.